Literature DB >> 25384306

Case report of a fatal intoxication by Nucynta.

Dori M Franco1, Zabiullah Ali, Barry Levine, Robert A Middleberg, David R Fowler.   

Abstract

Tapentadol (Nucynta) is a centrally acting opioid analgesic prescribed for the treatment of moderate to severe acute pain. Its efficacy is believed to be due to μ-opioid receptor agonist activity and inhibition of norepinephrine reuptake resulting in increased norepinephrine concentrations. There is only one other case in the literature relating to the toxicity of this agent or report of a fatality. This case report documents a case in which tapentadol was identified as the cause of death. The tapentadol concentration found in the heart blood submitted in this case was more than 20 times the upper limit of the therapeutic range. Possible mechanisms of death include respiratory depression, central nervous system depression, and serotonin syndrome. Based on the scene investigation and autopsy findings in this case, the medical examiner determined that the cause of death was narcotic (Nucynta) intoxication and the manner of death was undetermined.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25384306     DOI: 10.1097/PAF.0b013e3182887804

Source DB:  PubMed          Journal:  Am J Forensic Med Pathol        ISSN: 0195-7910            Impact factor:   0.921


  6 in total

1.  Comment on Tapentadol and Serotonin Syndrome.

Authors:  Michael E Mullins; William H Dribben
Journal:  Hosp Pharm       Date:  2017-04

2.  Probable Tapentadol-Associated Serotonin Syndrome After Overdose.

Authors:  Heather Walczyk; Cheuk H Michael Liu; Antonia Alafris; Henry Cohen
Journal:  Hosp Pharm       Date:  2016-04

3.  Spontaneously reported adverse drug events related to tapentadol and oxycodone/naloxone in Australia.

Authors:  Carmen Abeyaratne; Samanta Lalic; J Simon Bell; Jenni Ilomäki
Journal:  Ther Adv Drug Saf       Date:  2018-03-25

4.  Tapentadol shows lower intrinsic efficacy at µ receptor than morphine and oxycodone.

Authors:  Preeti Manandhar; Mark Connor; Marina Santiago
Journal:  Pharmacol Res Perspect       Date:  2022-02

5.  Prescribing trend of tapentadol in a Sydney local health district.

Authors:  Jennifer Mirabella; Deepa Ravi; Angela L Chiew; Nicholas A Buckley; Betty S Chan
Journal:  Br J Clin Pharmacol       Date:  2022-07-07       Impact factor: 3.716

Review 6.  Cardiac Arrest Following Drug Abuse with Intravenous Tapentadol: Case Report and Literature Review.

Authors:  Misbahuddin Khaja; George Lominadze; Konstantin Millerman
Journal:  Am J Case Rep       Date:  2017-07-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.